Pulmonary Embolism Short-term Clinical Outcomes Registry
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/21/2018 |
| Start Date: | August 2016 |
| End Date: | March 2020 |
| Contact: | Anthony Weekes, MD |
| Email: | anthony.weekes@carolinashealthcare.org |
| Phone: | 704-355-3181 |
Pulmonary Embolism Short-term Clinical Outcomes Registry (PE-SCOR)
The overall goal of this clinical research study is to prospectively assess primary outcomes
related to pulmonary embolism (PE) that occur immediately (within 5 days) and within 30 days.
The secondary goal is to compare validated prediction models and a modified European Society
of Cardiology (ESC) approach that is primarily right ventricle dysfunction (RVD) driven with
clinical risk assessment being secondary, and with primary outcomes of clinical deterioration
within 5 days.
related to pulmonary embolism (PE) that occur immediately (within 5 days) and within 30 days.
The secondary goal is to compare validated prediction models and a modified European Society
of Cardiology (ESC) approach that is primarily right ventricle dysfunction (RVD) driven with
clinical risk assessment being secondary, and with primary outcomes of clinical deterioration
within 5 days.
The investigators wish to develop the Pulmonary Embolism Short-term Clinical Outcomes
Registry (PE-SCOR). The investigators also wish to determine the incidence of death and
circulatory and respiratory deterioration, and administration of reperfusion therapy within 5
days in PE patients. The study will also evaluate the sensitivity, specificity and positive
and negative predictive values of each RVD assessment option. The investigators will also
derive a prediction model for PE patients for the primary outcome within five days. Finally,
investigators will determine the functional outcomes of PE patients 30 days after PE.
Registry (PE-SCOR). The investigators also wish to determine the incidence of death and
circulatory and respiratory deterioration, and administration of reperfusion therapy within 5
days in PE patients. The study will also evaluate the sensitivity, specificity and positive
and negative predictive values of each RVD assessment option. The investigators will also
derive a prediction model for PE patients for the primary outcome within five days. Finally,
investigators will determine the functional outcomes of PE patients 30 days after PE.
Inclusion Criteria:
- Patients 18 years or older with image confirmed acute pulmonary embolism diagnosed
within 12 hours of ED presentation will be eligible for enrollment.
Exclusion Criteria:
- Patients who refuse consent for 30-day clinical contact and follow-up.
We found this trial at
7
sites
Charlotte, North Carolina 28203
Principal Investigator: Anthony Weekes, MD
Phone: 704-620-2950
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials